📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sarthak Metals Q3 FY26: Revenue Grows 8% YoY to ₹47.73 Cr; Welding Volumes Surge 182%
Sarthak Metals Limited (SMLT) reported a steady Q3 FY26 performance with revenue from operations increasing 8% YoY to ₹47.73 crore and PAT rising 6% YoY to ₹1.30 crore. The core Cored Wire segment maintained stability with a 1% volume growth, while the new Welding division showed exceptional momentum with volumes surging 182% YoY to 409 tonnes. However, the Aluminium Flipping Coil segment faced significant headwinds, with volumes declining 37% YoY due to unethical competition and pricing distortions. The company is actively diversifying, with its Biotechnology pilot facility in Nagpur now operational and targeting the ethanol sector.
Key Highlights
Revenue from operations grew 8% YoY to ₹47.73 Cr and 31% QoQ, indicating a strong sequential recovery.
Welding business achieved ₹4.4 Cr revenue in Q3 with volumes of 409 tonnes, aiming for ₹25 Cr annual sales within two years.
EBITDA margins saw a slight contraction of 27 bps YoY to 4.41% due to international price disparities and raw material challenges.
Aluminium Flipping Coil segment revenue stood at ₹6 Cr, but operations are currently subdued due to unviable market pricing.
Biotechnology initiative is progressing with a 14 kg pilot facility operational in Nagpur and discussions ongoing with ethanol distilleries.
💼 Action for Investors
Investors should focus on the rapid scaling of the Welding division and the progress of the Biotechnology pilot as potential margin drivers. While the core steel-related segments face competitive and pricing pressures, the company's diversification strategy into import-substitution products like flux-cored wires warrants a watch.
Sarthak Metals Q3 FY26 Net Profit Rises 6.3% YoY to ₹1.30 Crore; Revenue Up 8.5%
Sarthak Metals Limited (SMLT) reported a steady performance for the quarter ended December 31, 2025, with revenue from operations growing 8.5% YoY to ₹47.73 crore. Net profit for the quarter saw a modest increase to ₹1.30 crore, up from ₹1.22 crore in the corresponding quarter of the previous year. The company continues to maintain a strong financial position with zero debt across all categories. For the nine-month period ended December 2025, the company achieved a total income of ₹131.55 crore and a net profit of ₹3.12 crore.
Key Highlights
Revenue from operations increased to ₹4,772.94 lakhs in Q3 FY26 compared to ₹4,399.70 lakhs in Q3 FY25.
Net profit for the quarter stood at ₹129.72 lakhs, reflecting a 6.3% growth over the previous year's ₹122.02 lakhs.
The company remains completely debt-free with zero outstanding loans or debt securities as of December 31, 2025.
Earnings Per Share (EPS) for the quarter improved to ₹0.95 from ₹0.92 YoY.
Inventory levels rose significantly to ₹3,765.76 lakhs from ₹2,742.11 lakhs in March 2025, suggesting preparation for higher demand.
💼 Action for Investors
The company's debt-free status and consistent profitability in a niche segment like cored wires make it a stable small-cap play. Investors should monitor if the high inventory levels translate into stronger sales growth in the final quarter of the fiscal year.
Sarthak Metals Expands Business Scope into Biotech and Specialty Chemicals via MOA Amendment
Sarthak Metals Limited (SMLT) has received shareholder approval to significantly diversify its business operations by adding biotechnology and specialty chemicals to its Memorandum of Association. This strategic shift allows the company to enter high-growth sectors including bio-fertilizers, pharmaceuticals, and nutraceuticals. Additionally, the company has secured the re-appointment of Mr. Sunil Dutt Bhatt as an Independent Director for a second five-year term effective from August 2026. These developments signal a long-term intent to move beyond traditional metal-related activities into diversified industrial segments.
Key Highlights
Shareholders approved the addition of Clause 9 to the MOA to include biotechnology, enzymes, and bio-based chemicals.
The new business scope covers R&D, manufacturing, and trading of pharmaceuticals, bio-inputs, and nutraceuticals.
Mr. Sunil Dutt Bhatt re-appointed as Independent Director for a 5-year term from August 3, 2026, to August 2, 2031.
The expansion includes provisions for technology transfer, consultancy, and contract research services.
Resolutions were passed via Postal Ballot which concluded on December 12, 2025.
💼 Action for Investors
Investors should monitor management's follow-up plans regarding capital allocation and project timelines for the new biotechnology vertical. While diversification reduces cyclical metal risk, the company's execution capability in these specialized sectors will be a key performance driver.